Business Context and Reporting Period
Company: Greenwich LifeSciences, Inc. (GLSI)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: GLSI is a clinical-stage biopharmaceutical company developing GLSI-100, an immunotherapy designed to prevent breast cancer recurrence. The company is currently conducting the Phase III Flamingo-01 clinical trial. As of June 30, 2024, the company had no commercial revenue and remains in a development phase.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 | Three Months Ended June 30, 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(5,079,877) | $(3,753,275) | $(2,606,682) |
| Net Loss Per Share (Basic & Diluted) | $(0.39) | $(0.29) | $(0.20) |
| Research & Development Expenses | $4,502,386 | $3,207,474 | $2,307,873 |
| General & Administrative Expenses | $696,219 | $781,434 | $353,531 |
| Cash and Cash Equivalents (End of Period) | $7,224,875 | $10,944,242 | N/A |
| Total Current Liabilities | $1,353,028 | $294,406 | N/A |
| Stockholders' Equity | $5,875,432 | $10,649,893 | N/A |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss for the six months ended June 30, 2024, increased by approximately $1.33 million (35%) compared to the same period in 2023, driven primarily by higher clinical and manufacturing costs.
- R&D Expense Growth: Research and development expenses rose 40% year-over-year for the six-month period, increasing from $3.21 million to $4.50 million.
- Liability Increase: Total current liabilities surged from $294,406 at year-end 2023 to $1.35 million at June 30, 2024. This increase is largely attributed to a rise in accounts payable and accrued interest.
- Capital Raises: The company raised approximately $3.07 million in net proceeds during the first half of 2024 through a private placement ($2.50 million) and an At-The-Market (ATM) program ($0.57 million).
Outlook, Risks, and Management Commentary
- Liquidity and Capital Resources: Management states that existing cash resources are expected to fund operations for the next 12 months. However, the company expects to continue incurring significant losses and will require additional capital to complete clinical trials and commercialization.
- Internal Control Weaknesses: Management concluded that disclosure controls and procedures were not effective as of June 30, 2024. Material weaknesses were identified due to inadequate segregation of duties, limited personnel, and insufficient written policies for accounting and IT.
- Related Party Transactions: The CEO, Snehal Patel, participated in a private placement on June 13, 2024, purchasing 174,825 shares for net proceeds of $2.50 million. He agreed to a one-year lock-up on these shares.
- Subsequent Events: Between July 1 and August 2, 2024, the company sold an additional 76,966 shares via its ATM program for net proceeds of $1.18 million.
- Risk Factors: The company faces risks related to its dependence on third-party manufacturers, the success of the Phase III trial, and the potential inability to raise future capital. There are no material pending legal proceedings.
Investor Verification Checklist
- Cash Runway: Verify if the $7.2 million cash balance is sufficient to sustain the accelerated R&D burn rate ($4.5M in six months) for the full 12-month period projected by management.
- Internal Controls: Review the remediation plan for the identified material weaknesses in internal controls over financial reporting.
- Related Party Concentration: Assess the impact of the CEO's recent $2.5 million investment and the associated lock-up agreement on future liquidity and governance.
- Liability Composition: Investigate the specific drivers of the $1.08 million increase in accounts payable and the $220,845 in accrued interest owed to the Henry M. Jackson Foundation.
- Dilution: Monitor the pace of share issuance under the ATM program and the potential dilution from outstanding options (1.5 million shares) and warrants (20,174 shares).